Cookie Preference

This website uses cookies to improve user experience. Please select an option.  Privacy Policy

No cookies except for those necessary for technical reasons are set.


8th BioVaria to Take Place in Munich on 11 May 2015

Ascenion unveils first technology highlights: MYDGF – a therapeutic protein candidate for cardiac repair following myocardial infarction

26 March 2015, Munich, Germany – On 11 May 2015, dealmakers and investors from the international biopharmaceutical industry will come together in Munich to discover the most promising life-science technologies as licensing or investment opportunities.

Top scientists from about 50 research institutes in 10 European nations and their technology transfer partners will present some 50 patent-protected technologies with strong commercial prospects: potential diagnostics and therapeutics as well as platform technologies. In addition, BioVaria’s Spin-off Panel will feature some of Europe’s most innovative start-ups.

A preview is now available. Ascenion and its partner institutes will showcase a total of five projects. One of them is MYDGF (myeloid-derived growth factor), a protein with exceptional therapeutic potential in myocardial infarction (MI) discovered at Hannover Medical School (MHH). Results have just been published in Nature Medicine. Prof. Wollert and his team at the MHH were first to reveal that the protein, which had hitherto been poorly characterized, is usually produced by bone marrow cells to protect and repair the heart after MI. Using a recombinant version of MYDGF, they also showed that it has multiple beneficial effects on heart function and survival in relevant in vivo models when applied systemically following MI.

‘The MHH approach provides new hope to many patients. About 1 million people in Germany and the United States alone experience acute myocardial infarction each year. And although acute care has dramatically improved over the last years, the loss of viable tissue and scar formation often leads to chronic heart dysfunction and eventually heart failure,’ comments Ralf Cordes, Ascenion’s Technology Manager at the MHH. He has closely worked together with the MHH team to ensure proper patent protection and is now helping to identify suitable development partners from industry.

Further BioVaria projects originating from Ascenion’s partners are:


  • Cystobactamides – novel antibacterials against gram-negative pathogens (Helmholtz Centre for Infection Research)
  • Marker for beta-cell maturation (Helmholtz Zentrum München)
  • Novel bispecific antibodies for treating HBV infection (Helmholtz Zentrum München, Technische Universität München, German Cancer Research Center)
  • Novel inhibitor of mutated IDH1 in cancer therapy (Hannover Medical School)

Find all technologies at


The proven BioVaria format with its short presentations, Spin-off Panel and all-day poster exhibition provides an unprecedented density of life-science innovation in just one day. At the same time, it allows plenty of opportunity for individual discussions with scientists and their technology transfer representatives.





Esther Lange
E: info(at)biovaria(dot)org
Ascenion GmbH, Herzogstraße 64, 80803 Munich, GERMANY



About BioVaria

BioVaria brings together European research institutions across national borders in order to improve the transfer of their research results into application. In just one day, it presents an unmatched density of highly innovative technologies to potential investors, collaboration partners and licensees from the international biopharmaceutical industry.


Key features of BioVaria:


  • Unique gathering of Europe’s top scientists, technology transfer professionals, investors and industry representatives.
  • Presentation of more than 50 licensable technologies and spin-offs originating from public research institutions and universities across Europe.
  • Focus on patent-protected, commercially attractive opportunities covering research tools, diagnostics and therapeutics in the fields of cancer, infectious diseases, metabolism, autoimmune and neurodegenerative disorders, and in other disease areas.
  • Interactive, efficient one-day format combining 10-min oral presentations with an all-day poster exhibition.
  • Spin-off Panel presenting promising European life-science start-ups.
  • Ample space to discuss scientific details face-to-face with the inventors.
  • Jointly organized by Ascenion and a selected group of leading European technology transfer organizations.


Patron: Bavarian Ministry of Economic Affairs and Media, Energy and Technology

Sponsors: BioM, Boehringer Ingelheim, Janssen-Cilag, MSD, HERTIN, LSP, Vossius & Partner, Pinsent Masons, TVM Capital

Technology transfer partners: Aalborg University, Ascenion, Austria Wirtschaftsservice Gesellschaft, Bayerische Patentallianz, Bio&Technology Innovations Platform, BTO - Bergen Teknologioverføring, CIBICAN, EMBLEM Technology Transfer, FIST, Helmholtz Zentrum München, IOCB TTO, Lead Discovery Center, Max-Planck-Innovation, MITO Technology, MRC Technology, PROvendis

Network partners: ASTP Proton, Bayern Innovativ, TTS Global Initiative

Communication partners: Business Wire, Current Partnering, GoingPublic, KONOCOM, transkript


About Ascenion

Ascenion GmbH is an IP asset management company with particular expertise in the life sciences. Ascenion advises and supports public research institutions with regard to the protection and exploitation of their intellectual property (patents, know-how, materials), and initiates and mediates license agreements between research institutions and industry. The company places particular emphasis on coaching company founders and on active equity management. Ascenion was founded in 2001 as a 100% subsidiary of the LifeScience Foundation for the Promotion of Science and Research and is technology transfer partner of 23 research institutes in the Helmholtz and Leibniz Associations, as well as of the Charité, the Hannover Medical School, the research institute TWINCORE and the Universität zu Lübeck. Ascenion currently markets around 750 technologies on behalf of these institutes, and closes an average of about 80 revenue-generating agreements between research and industry per year. The team has also coached numerous spin-offs through their foundation and early growth and Ascenion holds equity in 25 of these companies. Ascenion’s headquarters are in Munich, with further offices in Berlin, Braunschweig, Hamburg, Hanover and Neuherberg. 


Further information at